|
|
3701 Market Street, 4th Floor
Philadelphia, PA 19104 USA
phone:(267) 499-2014
fax:(267) 499-2015
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
30 |
|
|
| www.bionanomatrix.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Develops single-molecule analysis systems for applications in molecular biology, biomedical research, diagnostics and personalized medicine. |
|
| Management |
| Edward L. Erickson, President and CEO; Han Cao, Founder and Chief Scientific Officer; Michael Kochersperger, Vice President, Engineering; Lorraine LoPresti, Vice President, Finance & Administration and Chief Financial Officer; Gary Zweiger, Vice President, Business Development |
| |
|
|
| |
|
| Keywords |
| single molecule analysis, genome, genomics, DNA, assembly, mapping, structural variation, molecular diagnostics, personalized medicine |
|
|
|
| Description |
|
BioNanomatrix is developing pioneering nanoscale imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome. Until now, whole genome analysis has been prohibitively slow, complicated and expensive. BioNanomatrix is applying its patented nanoscale technology to develop a unique platform that can rapidly and cost effectively analyze individual long strands of DNA in sequence and in a massively parallel format. The BioNanomatrix technology delivers comprehensive analyses of DNA and other genome-related peptides and proteins with single-molecule and single-cell sensitivity, while avoiding the fragmentation and complex data re-assembly required by other approaches. The affordability, speed and simplicity of the technology are expected to make the routine use of genetic information feasible in broad-ranging applications including genetic diagnostics, personalized medicine and biomedical research
Until now, whole genome analysis has been prohibitively slow, complicated and expensive. BioNanomatrix is applying its patented nanoscale technology to develop a unique platform that can rapidly and cost effectively analyze individual long strands of DNA in sequence and in a massively parallel format. The BioNanomatrix technology delivers comprehensive analyses of DNA and other genome-related peptides and proteins with single-molecule and single-cell sensitivity, while avoiding the fragmentation and complex data re-assembly required by other approaches. The affordability, speed and simplicity of the technology are expected to make the routine use of genetic information feasible in broad-ranging applications including genetic diagnostics, personalized medicine and biomedical research |
|
| Products / Services |
Fundamentally, our products and business model are based on the classic razor/razorblade concept. Placements of our analysis platform, the nanoAnalyzerŪ 1000 in customer sites coupled with application development will drive the ongoing sale of nanochannel chips and proprietary reagents. Additionally, we believe significant revenue will be generated by value-added services, such as contract application development with business partners. Given the large array of opportunities before us, our strategy will be first to access unregulated markets that represent immediate opportunities that can be exploited with our current technology configuration consisting of nanochannel chips, the initial launch configuration instrumentation, basic software and simple protocols for the user. As our product line develops we intend to form partnerships with established diagnostics companies to exploit our technology in diagnostics.
|
|
| Technology / Differentiation |
| Our product offerings are based on systems consisting of our disposable nanochannel chip, reagents, analysis instrumentation, associated software, and standards/controls. The nanochannel chip is at the core of our technology and provides substantial and sustainable competitive advantages. This patented technology enables extremely rapid, single DNA molecule analysis using massively parallel nano-scale channels to create a powerful new genetic analysis platform. Sample DNA can literally be uncoiled and stretched (i.e. linearized) permitting labeling and reading of the DNA not unlike the reading of a bar code using an optical scanner. This DNA barcode provides structural and organizational information (i.e. structural variation) key to functional understanding of the genome. Because of its unique ability to unwind DNA with unprecedented speed and robustness, our technology and approach goes far beyond existing technologies in terms of the length of DNA fragments that can be analyzed and is much faster and ultimately less expensive than competitive methods. |
|
| Market / Customers |
We believe that our total available market is very large and can be segmented by: 1) type of customer -- academic and research institutions, enterprise customers (such as pharmaceutical, biotech and diagnostics companies) and diagnostic laboratories, such as reference and hospital labs and 2) specific functional applications -- DNA sizing/imaging, structural variation analysis, mapping, cytogenetics, cancer biomarker diagnostics, and pathogen detection. Individual market segments range in size from well-defined niches in the tens of millions of dollars per annum to very large opportunities in excess of a billion dollars. For example, the research markets for DNA sequencing and single nucleotide polymorphism (SNP) analysis are each in excess of $1B today as is the clinical diagnostic market for cytogenetic assays. Geographically, in addition to the U.S., China represents an already large and rapidly growing market opportunity. For example, the Beijing Genomics Institute (BGI) is one of the top genomics centers in the world.
|
|
| Competitors / Substitutes / Alternatives |
The field of single-molecule analysis is emerging and a number of smaller companies are developing single-molecule analysis products and service offerings for life science customers. Additionally, large life science "tools" companies, such as Affymetrix, Illumina, Life Technologies and others have demonstrated interest in this space. However, we believe our technology offers sustainable, competitive advantages over potentially competing technologies and alternative modalities such as sequencing. With respect to the latter, we are positioning our technology to be complimentary to sequencing in applications such as assembly and mapping.
|
|
| Strategy |
Our strategy is to exploit opportunities in large genome centers initially and develop applications, such as DNA sample quality analysis, mapping and assembly and structural variation analysis that serve these customers. We believe our platform technologies will find many applications in biomedical research and ultimately in diagnostic and personalized medicine applications.
|
|
| Funding |
| We have received approximately $23 million in funding to date consisting of venture capital, grant funding and a limited amount of bank debt. |
|
| Status |
| We are preparing to ship systems to selected external sites for beta testing beginning Q3 2010 and begin limited commercial release before the end of this year. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members